CN113303399A - Plant compound extract and preparation method thereof - Google Patents
Plant compound extract and preparation method thereof Download PDFInfo
- Publication number
- CN113303399A CN113303399A CN202110509205.2A CN202110509205A CN113303399A CN 113303399 A CN113303399 A CN 113303399A CN 202110509205 A CN202110509205 A CN 202110509205A CN 113303399 A CN113303399 A CN 113303399A
- Authority
- CN
- China
- Prior art keywords
- parts
- kelp
- extract
- plant compound
- sweet potato
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 52
- 239000000284 extract Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000605 extraction Methods 0.000 title claims description 9
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 59
- 241000196324 Embryophyta Species 0.000 claims abstract description 35
- 241000244987 Daiswa polyphylla Species 0.000 claims abstract description 24
- 240000003152 Rhus chinensis Species 0.000 claims abstract description 24
- 235000014220 Rhus chinensis Nutrition 0.000 claims abstract description 24
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 23
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 23
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 20
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 14
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 14
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 19
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 19
- 241001330002 Bambuseae Species 0.000 claims description 19
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 19
- 239000011425 bamboo Substances 0.000 claims description 19
- 239000003610 charcoal Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000011550 stock solution Substances 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 108010059820 Polygalacturonase Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 229940106157 cellulase Drugs 0.000 claims description 6
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 abstract description 7
- 229940088710 antibiotic agent Drugs 0.000 abstract description 7
- 239000000419 plant extract Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 33
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 20
- 239000002131 composite material Substances 0.000 description 16
- 229920001282 polysaccharide Polymers 0.000 description 16
- 239000005017 polysaccharide Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 14
- 150000004804 polysaccharides Chemical class 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- -1 triterpene compounds Chemical class 0.000 description 10
- 239000011787 zinc oxide Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 229920001543 Laminarin Polymers 0.000 description 8
- 239000005717 Laminarin Substances 0.000 description 8
- 241000282887 Suidae Species 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoyl acetaldehyde Chemical compound CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000001630 jejunum Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 102000000591 Tight Junction Proteins Human genes 0.000 description 5
- 108010002321 Tight Junction Proteins Proteins 0.000 description 5
- 235000019621 digestibility Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- 229940088592 immunologic factor Drugs 0.000 description 5
- 239000000367 immunologic factor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000003940 Occludin Human genes 0.000 description 4
- 108090000304 Occludin Proteins 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 241000015177 Saccharina japonica Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000985694 Polypodiopsida Species 0.000 description 3
- 102100038567 Properdin Human genes 0.000 description 3
- 108010005642 Properdin Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 3
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229940026314 red yeast rice Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- PVFGJHYLIHMCQD-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one Chemical compound C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 PVFGJHYLIHMCQD-UHFFFAOYSA-N 0.000 description 2
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000002029 Claudin Human genes 0.000 description 2
- 108050009302 Claudin Proteins 0.000 description 2
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 2
- 229920000855 Fucoidan Polymers 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 241000258937 Hemiptera Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- FNUPUYFWZXZMIE-LSDHHAIUSA-N (2r,3r)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-2,3-dihydrochromen-4-one Chemical compound C1([C@@H]2[C@H](C(C3=CC=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 FNUPUYFWZXZMIE-LSDHHAIUSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GDVRUDXLQBVIKP-HQHREHCSSA-N 1-O-galloyl-beta-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-HQHREHCSSA-N 0.000 description 1
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- GKAJCVFOJGXVIA-UHFFFAOYSA-N 4'-methoxy-3,3',5-stilbenetriol 3-glucoside Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 GKAJCVFOJGXVIA-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241001494508 Arundo donax Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- SLJTWDNVZKIDAU-SVAFSPIFSA-N Betulonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C SLJTWDNVZKIDAU-SVAFSPIFSA-N 0.000 description 1
- SLJTWDNVZKIDAU-CKURCAGRSA-N Betulonic acid Natural products CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@@H](CC[C@@H]4[C@@]5(C)CCC(=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O SLJTWDNVZKIDAU-CKURCAGRSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 1
- FNUPUYFWZXZMIE-UHFFFAOYSA-N Fustin Natural products O1C2=CC(O)=CC=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 FNUPUYFWZXZMIE-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920000296 Glucogallin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000745390 Lophatherum Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- LGXXLEPDYUEPOE-UHFFFAOYSA-N Paristerone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCCC33O)C)C3=CC(=O)C21 LGXXLEPDYUEPOE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- XBDSJIRUBIRQNC-UHFFFAOYSA-M S([O-])(O)=O.[Na+].C(CCCCCCCCC)(=O)CC=O Chemical compound S([O-])(O)=O.[Na+].C(CCCCCCCCC)(=O)CC=O XBDSJIRUBIRQNC-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- KVSNMTUIMXZPLU-XOZXFAFYSA-N friedelane Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC[C@@H]1C KVSNMTUIMXZPLU-XOZXFAFYSA-N 0.000 description 1
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 1
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 1
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000001309 inhibitory effect on influenza Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- NKMDIWKRKQFYPH-VIUFNMEASA-N lupane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C NKMDIWKRKQFYPH-VIUFNMEASA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- LSNUUAUXWJZSFD-FSDSQADBSA-N methyl (3r,4s,5r)-3,4,5-trihydroxycyclohexene-1-carboxylate Chemical compound COC(=O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1 LSNUUAUXWJZSFD-FSDSQADBSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NKDFYOWSKOHCCO-RIPMIKRDSA-N paristerone Chemical compound C1[C@@H](O)[C@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-RIPMIKRDSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 108010008929 proto-oncogene protein Spi-1 Proteins 0.000 description 1
- LVTJOONKWUXEFR-UEZXSUPNSA-N protodioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O LVTJOONKWUXEFR-UEZXSUPNSA-N 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- GKAJCVFOJGXVIA-QGLKVJOYSA-N rhaponticin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1O GKAJCVFOJGXVIA-QGLKVJOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- QDQWGYLCDZBAMD-UHFFFAOYSA-N saponin C Natural products CC1C2C3CCC4C5(C)CCC(O)C(C)(COC6OC(CO)C(O)C(O)C6O)C5CCC4(C)C3(C)CCC27C8OC8C1(C)OC7=O QDQWGYLCDZBAMD-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/14—Pretreatment of feeding-stuffs with enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a plant compound extract which can replace antibiotics to ensure the healthy growth of animals. Comprises the following components: 2-10 parts of paris polyphylla, 10-15 parts of lophatherum gracile, 10-15 parts of rhus chinensis, 10-15 parts of pteridophyte, 10-15 parts of houttuynia cordata, 18-20 parts of sweet potato and 25-30 parts of dried kelp.
Description
Technical Field
The invention relates to the field of plant extracts, in particular to a plant compound extract and a preparation method thereof.
Background
In the cultivation of livestock, aquatic products and the like, antibiotics are widely used in the process of epidemic disease prevention and treatment, so that the immunity of animals is reduced, endogenous infection is caused, and the drug resistance of the animals is enhanced; the environment also causes the quality to be reduced due to the drug residue of antibiotics; meanwhile, the feed also threatens human health and causes negative effects, so that all countries are in the feed for resisting antibiotics and chemosynthetic drugs by appointed laws and regulations.
In the work scheme of animal antibacterial use reduction action trial points (2018-2021) issued in rural agricultural departments, it is pointed out that by reducing the use of additives such as antibacterial in 3 years, the problems of drug residues and animal bacteria resistance should be effectively controlled.
Therefore, those skilled in the art should develop alternative products to replace antibiotics, thereby improving the physical quality of animals and reducing the environmental pollution.
Disclosure of Invention
The invention discloses a plant compound extract which can replace antibiotics to ensure the healthy growth of animals.
The invention provides a plant compound extract, which comprises the following components: 2-10 parts of paris polyphylla, 10-15 parts of lophatherum gracile, 10-15 parts of rhus chinensis, 10-15 parts of pteridophyte, 10-15 parts of houttuynia cordata, 18-20 parts of sweet potato and 25-30 parts of dried kelp.
Preferably, the composition is: 5 parts of paris polyphylla, 10 parts of lophatherum gracile, 15 parts of rhus chinensis, 10 parts of pteridophyte, 10 parts of houttuynia cordata, 20 parts of sweet potato and 30 parts of dried kelp.
Preferably, the sweet potatoes are fresh sweet potatoes.
The invention also provides a preparation method of the plant compound extract, which comprises the following steps:
(1) taking the components of the plant compound extract in the claims 1-3 as raw materials: root of Rhus chinensis Mill, herb of Paris polyphylla Smith, fern, herb of Lophatherum gracile Smith, herba Houttuyniae, sweet potato, and dried herba Zosterae Marinae;
(2) cleaning raw materials, drying in the shade, pulverizing, and mixing;
(3) steaming at 100-;
(4) sterilizing the stock solution, adsorbing with bamboo charcoal for 7-15 days, drying bamboo charcoal in the shade, grinding, separating bamboo charcoal to obtain the final product, and packaging.
Preferably, the bamboo charcoal is massive bamboo charcoal.
Preferably, the kelp is a dried kelp extract, and the extraction method comprises the following steps:
putting the dried kelp raw material into a closed container, completely freezing at the temperature of minus 30-minus 20 ℃, and repeating for 2-3 times when the kelp raw material is completely thawed at the temperature of 25-30 ℃;
drying the kelp: purified water is prepared according to the weight portion ratio of 1:10, and the pH value is 9: heating in water bath to 40-45 deg.C, maintaining the temperature for 1 hr, and stirring for 10-15 min; heating in water bath, maintaining the temperature, and stirring for 3-8 times;
adding alginate lyase and 2% complex enzyme according to 0.1% of the weight of the dry kelp, stirring for 3-8 hours at the temperature of 40-45 ℃ at the speed of 300-4000 r/min, centrifuging for 10-20 minutes at the speed of 3000-4000r/min, and performing solid-liquid separation to obtain a supernatant which is the kelp extract;
wherein the parameter of the alginate lyase is 1000U/mL;
the compound enzyme is pectinase, cellulase and protease, the ratio of the pectinase to the cellulase to the protease is 1:1:1, and the parameter is 2 ten thousand U/mL.
The plant compound extract provided by the invention comprises paris polyphylla, lophatherum gracile, rhus chinensis, fern, houttuynia cordata, sweet potatoes and dried kelp, and the natural extract is obtained by adopting the extraction method, and the components contain various plant polysaccharides, flavonoids, saponins, alkaloids, organic acids, vitamins and natural minerals, so that the extract has double functions of nutrition and medicine, can promote the glycometabolism of the organism, promote the synthesis of proteins and enzymes, increase the antibody titer of the organism and stimulate the gonadal development, and has the functions of sterilization, bacteriostasis, regulation of the immunity of the organism and nonspecific antibiosis.
Furthermore, the plant raw materials are easy to obtain, and the extraction method is easy to popularize and meets the production requirements.
Drawings
FIG. 1 shows the results of a plant compound extract and its preparation method and the effect of the compound plant extract on the expression of immune factors and tight junction proteins in the jejunum (A), duodenum (B) and ileum (C) of weaned pigs in analysis.
Detailed Description
The invention discloses a plant compound extract and a preparation method thereof, which can replace antibiotics to ensure the healthy growth of animals.
The technical solutions in the embodiments of the present invention are described in detail below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a plant compound extract, which comprises the following components: 2-10 parts of paris polyphylla, 10-15 parts of lophatherum gracile, 10-15 parts of rhus chinensis, 10-15 parts of pteridophyte, 10-15 parts of houttuynia cordata, 18-20 parts of sweet potato and 25-30 parts of dried kelp.
Preferably, the composition is: 5 parts of paris polyphylla, 10 parts of lophatherum gracile, 15 parts of rhus chinensis, 10 parts of pteridophyte, 10 parts of houttuynia cordata, 20 parts of sweet potato and 30 parts of dried kelp.
Preferably, the sweet potatoes are fresh sweet potatoes.
The invention also provides a preparation method of the plant compound extract, which comprises the following steps:
(1) taking the components of the plant compound extract in the claims 1-3 as raw materials: root of Rhus chinensis Mill, herb of Paris polyphylla Smith, fern, herb of Lophatherum gracile Smith, herba Houttuyniae, sweet potato, and dried herba Zosterae Marinae;
(2) cleaning raw materials, drying in the shade, pulverizing, and mixing;
(3) steaming at 100-;
(4) sterilizing the stock solution, adsorbing with bamboo charcoal for 7-15 days, drying bamboo charcoal in the shade, grinding, separating bamboo charcoal to obtain the final product, and packaging.
Preferably, the kelp is a dried kelp extract, and the extraction method comprises the following steps:
putting the dried kelp raw material into a closed container, completely freezing at the temperature of minus 30-minus 20 ℃, and repeating for 2-3 times when the kelp raw material is completely thawed at the temperature of 25-30 ℃;
drying the kelp: purified water is prepared according to the weight portion ratio of 1:10, and the pH value is 9: heating in water bath to 40-45 deg.C, maintaining the temperature for 1 hr, and stirring for 10-15 min; heating in water bath, maintaining the temperature, and stirring for 3-8 times;
adding alginate lyase and 2% complex enzyme according to 0.1% of the weight of the dry kelp, stirring for 3-8 hours at the temperature of 40-45 ℃ at the speed of 300-4000 r/min, centrifuging for 10-20 minutes at the speed of 3000-4000r/min, and performing solid-liquid separation to obtain a supernatant which is the kelp extract;
wherein the parameter of the alginate lyase is 1000U/mL;
the compound enzyme is pectinase, cellulase and protease, the ratio of the pectinase to the cellulase to the protease is 1:1:1, and the parameter is 2 ten thousand U/mL.
The extraction method reduces cell wall activity by quick freezing and quick warming, forces the kelp cell to be in a state of easy damage, and directly breaks partial cell products, thereby performing water bath and stirring to effectively improve extraction amount.
The method comprises the following steps:
(1) taking the following components: cleaning Paris polyphylla whole grass, lophatherum gracile whole grass leaves, rhus chinensis roots, ferns, houttuynia cordata, sweet potatoes and dry kelp, drying in the shade in a sterile manner, and crushing the components for later use;
(2) mixing the components according to the parts by weight, steaming at the temperature of 100-120 ℃, and naturally cooling to normal temperature;
(3) adding red yeast rice after steaming, and fermenting for 7-15 days to obtain a fermented semi-finished product;
the weight parts of the addition amount of the red yeast rice are as follows: the components (Paris polyphylla whole grass, lophatherum gracile whole grass leaf, Salicomia Herbacea root, fern, houttuynia cordata, sweet potato and dried kelp): red yeast rice 100: 2-5;
(4) filtering the semi-finished product to remove residues to obtain stock solution, and sterilizing;
(5) adsorbing the sterilized stock solution with bamboo charcoal blocks for 7-15 days, air drying the bamboo charcoal at low temperature, and grinding to obtain bamboo charcoal powder and stock solution mixture;
(6) separating bamboo charcoal to obtain plant compound extract;
wherein, paris polyphylla and the whole grass thereof are plants of paris of liliaceae, and the chemical components of the paris polyphylla are rich in paris polyphylla saponin A, paris polyphylla saponin A, B, paris polyphylla saponin C, D, E, F, G, H, paris polyphylla sterone (parister-one), creatinine (creatinine), amino acid and the like. Has effects in removing toxic materials, resisting cancer, relieving swelling and pain, clearing away heat, arresting convulsion, relieving cough, and relieving asthma.
Experiments prove that the paris polyphylla has the antibacterial effect that the water infusion and the decoction have the inhibition effect on typhoid bacillus, paratyphoid bacillus A, shigella and shigella flexneri in vitro, and the biological water infusion has stronger antibacterial effect than the decoction. The alcohol extract has obvious sedative and analgesic effects.
Paris polyphylla has antibacterial effect to Staphylococcus aureus, hemolytic streptococcus, meningococcus, dysentery bacillus, typhoid bacillus, paratyphoid bacillus, Escherichia coli and Pseudomonas aeruginosa.
It has obvious inhibition effect on dysentery bacillus, serratia marcescens, colibacillus, sensitive and drug-resistant staphylococcus aureus in vitro; it has inhibitory effect on influenza A virus and influenza Asian A virus, and has effect in killing leptospira, and is not suitable for decoction of water with the same concentration. Can inhibit the growth of HeLa tumor strain and L929 tumor strain in vitro; in vivo experiments, the composition is effective on Ehrlich ascites tumor EAC; the total saponins can also inhibit the growth of H22 solid tumor.
The whole herb of paris polyphylla is the part with the strongest effect in paris polyphylla and is the part which is most convenient to prepare.
Lophatherum gracile and the whole herb thereof are perennial herbs of Lophatherum of Gramineae. The stem and the leaf of the plant contain triterpene compounds: arundo donax, imperatorin, taraxasterol and friedelin; the aerial part contains phenolic components, amino acids, organic acids, and saccharides.
The folium Bambusae contains abundant flavonoids, biological polysaccharides and other effective components, such as phenolic acid compounds, anthraquinone compounds, terpene lactone, special amino acids, and trace elements such as active manganese, zinc, and selenium. The functional factors contained in the lophatherum gracile leaves mainly comprise flavone glycoside and coumarin lactone.
The active ingredients of the lophatherum gracile extract comprise flavone, phenolic acid, anthraquinone, lactone, polysaccharide, amino acid, trace elements and the like, and the lophatherum gracile extract has excellent effects of resisting free radicals, resisting oxidation, resisting aging, resisting fatigue, reducing blood fat, preventing cardiovascular and cerebrovascular diseases, protecting liver, expanding capillary vessels, dredging microcirculation, activating brain, promoting memory, improving sleep, resisting cancers, beautifying skin and the like.
The bamboo leaf flavone has small molecular weight and can be absorbed by human body, can effectively remove free radical and ester peroxide and block the synthesis of strong carcinogen N-nitrous acid amine compound, can obviously improve the immunity of the organism, resist diseases, regulate blood pressure, reduce blood fat and improve cerebral ischemia, and simultaneously has high-quality active ingredients and biological effects of resisting fatigue and aging.
The modern pharmacological experiments prove that the lophatherum gracile has the effects of relieving fever, promoting urination, inhibiting bacteria, resisting tumors and increasing blood sugar. Can obviously increase the chloride excretion in urine while promoting urination. The specific antibacterial effect is that the decoction has an inhibitory effect on staphylococcus aureus and hemolytic streptococcus.
Rhus chinensis Mill root is root of Rhus chinensis Mill of Anacardiaceae. Its main functions are clearing away heat and toxic material, removing blood stasis and stopping bleeding. Has effects in expelling pathogenic wind, eliminating dampness, relieving swelling, and softening hard masses. In terms of pharmacology, it has the effects of increasing coronary blood flow, resisting bacteria and viruses.
The main components of the composition comprise: the triterpenes are 9 compounds, and are divided into dammarane type, friedelane type, and lupane type, wherein hemiptera rhus chinensis lactone and hemiptera rhus chinensis acid are separated from bark of Rogowski drumstick. 3-keto-6-beta-hydroxy-oleanane-12-alkene-28-acid, 3-keto-6-beta-hydroxy-oleanane-18-alkene-28-acid, betulin and betulonic acid are also separated from the rhus chinensis root respectively.
The flavonoids comprise 10 compounds, such as quercetin, fisetin, 3', 4', 7-trihydroxyflavone, dihydrofisetin, rhus chinensis chalcone A, rhaponticin, rhus chinensis biflavone A, etc.
The tannin and the phenolic acid are separated from the rhus chinensis to obtain 13 compounds: gallic acid, ethyl gallate, methyl shikimate, 3, 5-dihydroxytoluene, 3-hydroxy-5-methylphenol-1-o- β -D- (6 '-gallic acid) glucofuranoside, 3-hydroxy-5-methylphenol-1-o- β -D- (6' -gallic acid) glucose), 3, 4, 5-trimethoxyphenyl-1-o- β -D-glucopyranose), 2[2, 3 dihydroxy-1- (4-hydroxyphenyl) propyl ] -5-methylbenzene-1, 3-diol, pentagalloyl glucose, rhamnolactone A, and the like.
Polysaccharides and other polysaccharide-like substances are important bioactive substances in animals and plants. The rhus chinensis root polysaccharide mainly comprises galactose, galacturonic acid, glucuronic acid and the like.
The effective components of the rhus chinensis root are as follows: contains tannin 50-70%, and most of tannin 80% in some regions, mainly galloyl glucose, free gallic acid, fat, resin, and starch; and organic acids including malic acid, tartaric acid, citric acid, and the like.
Ferns, also known as ferns, are a group of spore plants with the highest level of evolution. The fern contains various alkaloids, phenols, flavones, zizi and triterpenes, has physiological activity, and has antibacterial and bacteriostatic effects.
The houttuynia cordata is a herbal medicine recorded in Chinese pharmacopoeia, and the character of the herbal medicine is that the stem is in a flat cylinder shape, is twisted, has a length of 20-35 cm and a diameter of 0.2-0.3 cm; the surface is brownish yellow, has a plurality of longitudinal edges and obvious sections, and residual fibrous roots are arranged on the lower sections; is brittle and easy to break.
It is cold and cool in nature and enters lung meridian. It has effects of clearing away heat and toxic materials, relieving swelling, treating sore, inducing diuresis, removing dampness, clearing away heat, relieving dysentery, invigorating stomach, and resolving food stagnation, and can be used for treating lung abscess, pyocutaneous disease, hemorrhoid hematochezia, and spleen and stomach heat accumulation due to excess heat, heat toxin, dampness pathogen, and disease heat. Modern pharmacological experiments show that the product has antibacterial, antiviral, immunity improving, and diuretic effects.
The pharmacology comprises the following steps: in the aspect of enhancing immunity, enhancing phagocytic capacity of WBC and improving serum properdin, and when the medicine is used for treating chronic tracheitis, the synthesized houttuynin can obviously improve the phagocytic capacity of WBC of a patient on staphylococcus albus and obviously improve the serum properdin. Has antibacterial effect, and can inhibit various microorganisms (especially yeast and mold), hemolytic streptococcus, Staphylococcus aureus, Bacillus influenzae, Catalpus, and pneumococcus. It also has effect on Escherichia coli, Bacillus dysenteriae, and Bacillus typhonii, and the synthetic decanoyl acetaldehyde sodium bisulfite adduct is called synthetic houttuynin. In the aspect of virus action, the houttuynia cordata has an inhibition effect on influenza Asia A virus, influenza virus and influenza virus. In the function of diuresis, the blood capillary can be expanded, and the blood flow and urine secretion are increased, so that the function of diuresis is achieved. On the immune system, the houttuynine sodium bisulfite can improve the phagocytic function of white blood cells of chronic tracheitis patients and improve the serum properdin level. In the anti-tumor effect, the mouse is injected with different doses of the new houttuynine sodium bisulfite at different time, the total number of cancer cells, the division index of the cancer cells and the abdominal water volume are all obviously reduced, and the cAMP level in the cancer cells is increased. In the aspect of anti-inflammatory action, the composition can obviously inhibit the thermal denaturation of human gamma-globulin in the presence of Cu + +, also has obvious inhibition effect on dye exudation of abdominal capillary vessels caused by HCA, and can obviously inhibit capillary hyperfunction in the early stage of inflammation.
The sweet potato, also called sweet potato, is rich and rich in nutrition, protein, fat, polysaccharide, phosphorus, calcium, potassium, carotene, vitamin A, vitamin C, vitamin E, vitamin B1, vitamin B2 and 8 kinds of amino acids.
The protein content, carotene content and vitamin A content of the fertilizer are 3-100 times different from those of similar crops.
Dried kelp is prepared by drying fresh kelp in the sun and extracting the extract of kelp by a certain means. The kelp is marine vegetables with rich nutritive value, is rich in algal polysaccharides, proteins, fat, vitamins and mineral substances, also contains growth regulating substances such as cytokinin, auxin and phenols, antibiotic substances, and also contains components such as iodine, potassium, calcium, iron, manganese, titanium and the like which cannot be compared with common terrestrial plants. Alginic acid, a polysaccharide carbohydrate extracted from kelp, is an important active substance.
A herba Zosterae Marinae extract is prepared from leaves of herba Zosterae Marinae of Laminariaceae by breaking cell wall by physical, chemical or biological technique, and extracting intracellular substances. The material contains large amount of seaweed polysaccharide, mannitol, amino acids, vitamins, minerals, phytohormones, betaine, etc. Has antioxidant, anticoagulant, antitumor, antibacterial, blood pressure lowering, and radioprotective effects.
In the aspect of traditional Chinese medicine, the primary kelp is a cold and cool substance, and a large amount of edible primary kelp can cause sweating due to deficiency of human bodies, and is particularly obvious in spleen and stomach, but the primary kelp contains abundant nutrient substances, so that the effective utilization of kelp nutrients is realized by extracting effective substances in the kelp, and meanwhile, the problem of cold and cool primary kelp discussed in the aspect of traditional Chinese medicine can be avoided.
The kelp extract has antioxidant effect, and the ethyl acetate extracted from the kelp extract has higher capability of removing various free radicals than that of an antioxidant 2, 6-di-tert-butyl and is dose-dependent; both the kelp polyphenol and the kelp polysaccharide have antioxidant activity.
The laminarin extract has an anti-tumor effect, and multiple experiments show that different doses of laminarin are used for intragastric administration to mice, and the results show that the laminarin can obviously enhance the T lymphocyte proliferation capacity of normal mice and immunosuppressed mice and can improve the activity of NK cells. The kelp polysaccharide sulfate with different concentrations is used for treating the HeLa cell, and the kelp polysaccharide sulfate can inhibit the growth of human cervical cancer cell lines and can regulate and control the expression of bc-l2 protein and NF-JB p65 to influence the apoptosis of the cervical cancer cell. When the antitumor activity of the crude extract of the kelp polyphenol is measured by an MTT method, the kelp polyphenol has certain inhibition effect on cancer cells such as A549, P388, BEL-7402, Hela and the like.
The kelp extract has antibacterial effect, and has obvious inhibiting effect on Bacillus subtilis, Escherichia coli, Tetracoccus tetragonorrhoeae and Staphylococcus aureus, and the diluted extract has inhibiting effect on strains.
The kelp extract has the function of reducing blood sugar, the polysaccharide substance of the kelp extract can obviously reduce the blood sugar and urea nitrogen of a diabetic mouse, increase the serum calcium and serum insulin content of the diabetic mouse, has obvious recovery function on islet injury caused by alloxan, and the kelp polysaccharide has the functions of reducing blood sugar and protecting islet cells of the diabetic mouse.
The Laminaria japonica extract has radiation protection effect, and laminarin has obvious improvement effect on sexual function of male rats with reproductive system damaged by ionizing radiation, and can shorten erection latent period and straddling latent period of penis. Daily exposure to ultraviolet radiation reduced the levels of malondialdehyde and hydrogen peroxide in the skin tissue of the high dose laminarin mice, and increased the levels of catalase, hydroxyproline, type I collagen mRNA, SO, glutathione peroxidase, and serum NO. Meanwhile, an ultramicro electron microscope shows that the MVEC cell membranes of the group of mice are complete, and the mitochondrial cristae is clear. The laminarin is shown to be capable of enhancing the oxidation resistance of the skin, regulating the synthesis of skin collagen and protecting skin MVEC cells.
The laminaria japonica aresch extract has the functions of resisting fatigue and anoxia, and the test mice fed with laminaria japonica aresch undergo continuous 10-day fatigue-resisting and closed anoxia tests, and the results show that the test mice have obviously prolonged heavy-load swimming time and survival time under normal-pressure anoxia, and obviously raised hemoglobin content, so that the laminaria japonica aresch polysaccharide has better anoxia-resisting effect and antifatigue effect. Through the blood gas analysis of the hypoxic mouse, the laminarin is proved to improve the utilization rate of the hypoxic mouse tissue to oxygen again.
The herba Zosterae Marinae extract has immunoregulation effect, and can be used for regulating immunity of mouse with hypoimmunity.
The kelp extract has anticoagulant and antithrombotic effects, and the laminarin can obviously prolong the blood Activated Partial Thrombin Time (APTT), Prothrombin Time (PT) and whole blood Coagulation Time (CT) of the domestic rabbit, and has obvious dose effect, which indicates that the kelp cell wall polysaccharide has certain anticoagulant effect. The fucoidan sulfate with low molecular weight in herba Zosterae Marinae can inhibit thrombosis by inhibiting tissue factor pathway in extrinsic coagulation pathway. Compared with the time of full occlusion of the blood vessel, the antithrombotic capacity is enhanced along with the increase of the molecular weight of the fucoidan sulfate.
Example 1
The preparation method of the plant compound extract comprises the following steps:
(1) taking the components of the plant compound extract as raw materials: 1500g of rhus chinensis root, 500g of whole herb of seven-leaf and one-branch flowers, 1000g of fern, 1000g of whole herb of lophatherum gracile, 1000g of houttuynia cordata, 2000g of sweet potato and 3000g of dried kelp;
(2) cleaning raw materials, drying in the shade, pulverizing, and mixing;
(3) steaming at 100-;
(4) sterilizing the stock solution, adsorbing with bamboo charcoal for 7-15 days, drying and grinding the bamboo charcoal in the shade, and separating the bamboo charcoal to obtain the final product.
Example 2
Substantially the same as in example 1, except that the step (1):
(1) taking the components of the plant compound extract as raw materials: 1500g of rhus chinensis root, 1000g of paris polyphylla whole plant, 1000g of fern, 1500g of lophatherum gracile whole plant, 1000g of houttuynia cordata, 2000g of sweet potato and 3000g of dried kelp.
The antibiotic (taking zinc oxide as an example) is replaced by the compound extract of the plant.
The problem of diarrhea easily occurs in the creep period of 2 weeks after weaning of piglets is that the milk is taken as the piglet of a nutrition source, the intestinal tract of the piglet is not completely developed in the weaning period, the change of the intake nutrition type, the change of the living environment and the like easily cause the influence of the piglet on nutrition, physiology and psychological stress sources to cause the problems of the type and the function disorder of intestinal tract strains, the barrier function disorder of the intestinal tract and the like, and further cause the production performance of the piglet caused by the diarrhea.
In the prior art, high-content zinc oxide is added into piglet feed to inhibit diarrhea and improve the production performance of piglets.
The health of piglets is affected by using zinc oxide in high dose for a long time, and residual zinc element is discharged along with excrement of piglets, so that environment pollution such as soil is caused, and adverse effects on plants or crops are caused; if zinc enters water resources, it will accumulate in the water supply chain, eventually inducing the generation of drug-resistant bacteria.
The experiment aims to research the influence of the compound plant extract on the diarrhea, the growth performance, the intestinal development and the organism immunity of the piglets in the weaning creep stage instead of zinc oxide.
The experimental method comprises the following steps: 24 first-weaned piglets of 28-day-old binary first-born weaned pigs with the weight of 8.2 +/-1.78 kg are randomly divided into two groups, each group is divided into six repetitions, each repetition is divided into two repetitions, and the test period is 14 days. The control group (CON group) added 2kg/t zinc oxide to the basal diet, and the compound plant extract group (CPE group) added 1kg/t compound plant extract to the basal diet instead of the zinc oxide in the control diet.
The results show that: after the compound plant extract is used for replacing zinc oxide, the weaned piglets do not show significant differences in apparent digestibility, diarrhea rate, growth performance and intestinal mucosa barrier (P is more than 0.05); compared with a CON group, the CPE group remarkably improves the lgA and lgG content (P is less than 0.01) in the serum of the weaned piglets and remarkably reduces the ALP and ALT content (P is less than 0.01); in terms of maintaining the intestinal morphology intact and healthy, the villus height and villus cryptic ratio of duodenum in CPE group were significantly higher than in CON group (P < 0.05).
And (4) conclusion: the results show that the composite plant extract can replace zinc oxide to achieve better effects in the aspects of diarrhea resistance, growth promotion, organism immunity improvement and intestinal mucosa barrier maintenance. Compared with zinc oxide, the compound plant extract with a certain amount is added into the daily ration, so that the immunity of weaned piglets can be improved more obviously, the oxidative stress caused by weaning can be relieved, the integrity and the health degree of intestinal tracts can be maintained, and the economic benefit can be improved.
Results and analysis
Influence of composite plant extract on growth performance of weaned piglets
As shown in the following Table 1, the results of the composite plant extract group and the control group have no significant difference in terms of average daily gain, feed intake, feed-to-feed ratio, diarrhea rate, etc. (P > 0.05). However, the material weight of the composite plant extract group is lower than that of the control group.
TABLE 1 Effect of composite plant extracts on growth Performance and diarrhea Rate of weaned piglets
Second, the influence of the compound plant extract on the apparent digestibility of the nutrient substances of the weaned pigs
As can be seen from table 2, after the composite plant extract is used to replace high-dose zinc oxide, the nutrient apparent digestibility of piglets is not significantly affected, and the crude protein and crude fat digestibility of piglets in the composite plant extract group is only numerically higher than that in the control group. In the content of zinc in the feces, the difference between the two groups is very significant (P < 0.01), and the zinc element discharged by the compound plant extract group is far less than that discharged by the control group.
TABLE 2 Effect of composite plant extracts on apparent digestibility and Zinc emission of weaned piglets
Wherein, the zinc content in the excrement is recorded as zinc element.
Third, the influence of the compound plant extract on the serum biochemical indexes of weaned pigs
As can be seen from Table 3, compared with the control group, the ALP and ALT activities of the weaned piglets in the compound plant extract group are remarkably reduced (P < 0.05), and the AST activity of the weaned piglets in the compound plant extract group is also reduced (P < 0.05 ≦ P < 0.10). The composite plant extract group showed no significant difference (P > 0.05) from the control group in TP and ALP activities.
TABLE 3 Effect of composite plant extracts on serum biochemical indicators of weaned piglets
Fourth, the influence of the compound plant extract on the serum immunity index of the weaned pig
As can be seen from Table 4, in terms of the immune index to the serum of the weaned pig, the contents of lgA and lgG in the serum of the piglet of the compound plant extract group are higher than those of the control group, and the difference reaches a significant level (P < 0.05), while the content of lgM in the serum of the piglet of the compound plant extract group is similar to that of the control group.
TABLE 4 influence of composite plant extracts on serum immune index of weaned piglets
Fifthly, the influence of the composite plant extract on the intestinal form of weaned pigs
As can be seen from Table 5, the intestinal morphology of the ileum of the piglets in the composite plant extract group is not significantly different from that of the control group in terms of the influence on the intestinal morphology of the weaned piglets (P is more than 0.05), and is only numerically superior; in the jejunum, the crypt depth of the piglets of the composite plant extract group is reduced (P is more than or equal to 0.05 and less than 0.10), and the crypt ratio is increased (P is more than or equal to 0.05 and less than 0.10); in duodenum, the crypt depth of piglets in the compound plant extract group was significantly lower than that in the control group (P < 0.05), and the villous cryptic ratio was significantly higher than that in the control group (P < 0.05).
TABLE 5 Effect of composite plant extracts on weaned piglet intestinal morphology
Sixth, the influence of the compound plant extract on the expression of intestinal immune factors and tight junction protein of weaned pigs
The effect of the compound plant extract on the content of immune factors in different intestinal sections of weaned pigs and the expression of tight junction proteins thereof is shown in figure 1 (figure 1 shows the effect of the compound plant extract on the expression of immune factors and tight junction proteins in jejunum (A), duodenum (B) and ileum (C) of the weaned pigs). No significant difference was observed in the change of the contents of the respective immune factors (P > 0.05) in the jejunum, duodenum and ileum, and the contents of type II interferon (gamma-IFN) were low in the jejunum and duodenum of piglets in the composite plant extract group. In the aspect of tight junction protein, the intestinal mucosa zonula occludens-1 (ZO-1), Occludin (Occludin) and transmembrane protein (Claudin) in the intestinal tract of the weaned piglets of the compound plant extract group and the control group have no significant difference (P is more than 0.05), and the expression levels of Claudin in the jejunum, Occludin in the duodenum, ZO-1 and Occludin in the ileum of the weaned piglets of the compound plant extract group are numerically higher than those of the control group.
The above detailed description of the plant compound extract and the preparation method thereof provided by the present invention is provided, and a person skilled in the art may change the concept of the embodiments of the present invention in terms of the specific implementation and the application scope, and in summary, the content of the present description should not be construed as limiting the present invention.
Claims (5)
1. The plant compound extract is characterized by comprising the following components: 2-10 parts of paris polyphylla, 10-15 parts of lophatherum gracile, 10-15 parts of rhus chinensis, 10-15 parts of pteridophyte, 10-15 parts of houttuynia cordata, 18-20 parts of sweet potato and 25-30 parts of dried kelp.
2. The plant compound extract as claimed in claim 1, which is characterized by comprising the following components: 5 parts of paris polyphylla, 10 parts of lophatherum gracile, 15 parts of rhus chinensis, 10 parts of pteridophyte, 10 parts of houttuynia cordata, 20 parts of sweet potato and 30 parts of dried kelp.
3. The plant compound extract as claimed in claim 1, wherein the sweet potato is fresh sweet potato.
4. The preparation method of the plant compound extract is characterized by comprising the following steps:
(1) taking the components of the plant compound extract in the claims 1-3 as raw materials: root of Rhus chinensis Mill, herb of Paris polyphylla Smith, fern, herb of Lophatherum gracile Smith, herba Houttuyniae, sweet potato, and dried herba Zosterae Marinae;
(2) cleaning raw materials, drying in the shade, pulverizing, and mixing;
(3) steaming at 100-;
(4) sterilizing the stock solution, adsorbing with bamboo charcoal for 7-15 days, drying bamboo charcoal in the shade, grinding, separating bamboo charcoal to obtain the final product, and packaging.
5. The preparation method of the plant compound extract as claimed in claim 4, wherein the kelp is a dried kelp extract, and the extraction method comprises:
putting the dried kelp raw material into a closed container, completely freezing at the temperature of minus 30-minus 20 ℃, and repeating for 2-3 times when the kelp raw material is completely thawed at the temperature of 25-30 ℃;
drying the kelp: purified water is prepared according to the weight portion ratio of 1:10, and the pH value is 9: heating in water bath to 40-45 deg.C, maintaining the temperature for 1 hr, and stirring for 10-15 min; heating in water bath, maintaining the temperature, and stirring for 3-8 times;
adding alginate lyase and 2% complex enzyme according to 0.1% of the weight of the dry kelp, stirring for 3-8 hours at the temperature of 40-45 ℃ at the speed of 300-4000 r/min, centrifuging for 10-20 minutes at the speed of 3000-4000r/min, and performing solid-liquid separation to obtain a supernatant which is the kelp extract;
wherein the parameter of the alginate lyase is 1000U/mL;
the compound enzyme is pectinase, cellulase and protease, the ratio of the pectinase to the cellulase to the protease is 1:1:1, and the parameter is 2 ten thousand U/mL.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110509205.2A CN113303399A (en) | 2021-05-11 | 2021-05-11 | Plant compound extract and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110509205.2A CN113303399A (en) | 2021-05-11 | 2021-05-11 | Plant compound extract and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113303399A true CN113303399A (en) | 2021-08-27 |
Family
ID=77372995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110509205.2A Pending CN113303399A (en) | 2021-05-11 | 2021-05-11 | Plant compound extract and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113303399A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111387345A (en) * | 2020-01-09 | 2020-07-10 | 广东华膳康生物工程科技有限公司 | Compound polysaccharide composition and preparation method thereof |
-
2021
- 2021-05-11 CN CN202110509205.2A patent/CN113303399A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111387345A (en) * | 2020-01-09 | 2020-07-10 | 广东华膳康生物工程科技有限公司 | Compound polysaccharide composition and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
杨晋: "海藻多糖替代抗生素对断奶仔猪长性能和肠道屏障功能的影响", 《中国优秀硕士学位论文全文数据库(电子期刊)》 * |
胡凯光: "《核工业生物学》", 28 February 2015 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meireles et al. | A review of properties, nutritional and pharmaceutical applications of Moringa oleifera: integrative approach on conventional and traditional Asian medicine | |
CN102273639B (en) | Nidus collocaliae perfume (or spice) system product and preparation method thereof | |
CN104161187B (en) | A kind of poultry Chinese herbal feed additive, preparation method and application | |
JP2003192605A (en) | Lipase inhibitant | |
CN109527260B (en) | Compound bioactive feed additive for poultry and preparation method thereof | |
CN107660795A (en) | One kind prevention gout plaster taste and preparation method thereof | |
CN111631401A (en) | Traditional Chinese medicine enzyme and preparation method thereof | |
CN112336815A (en) | Anti-aging composition for strengthening body, preventing cancer and conditioning hypertension, hyperglycemia and hyperlipidemia and application thereof | |
KR20110128385A (en) | The herb medicine composition material and the manufacturing process for pimple skin-improvement uses by midam cheonggyeolan | |
KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
CN104208224B (en) | A kind of broiler compound traditional Chinese medicine composite and its preparation method and application | |
CN104479964A (en) | Hibiscus esculentus-fungus-algae health wine and preparation method thereof | |
CN111387345A (en) | Compound polysaccharide composition and preparation method thereof | |
CN114796392B (en) | Traditional Chinese medicine composition for treating gout and application thereof | |
CN110051598A (en) | A kind of pet skin care cleaning solution and preparation method thereof | |
CN113303399A (en) | Plant compound extract and preparation method thereof | |
CN113648377A (en) | Composition for relieving depression and soothing nerves and preparation method thereof | |
CN103719542B (en) | Compound microorganism active additive and applications thereof | |
CN112043730A (en) | Traditional Chinese medicine biological preparation for preventing and treating animal epidemic diseases | |
CN106173240A (en) | A kind of liver protecting function and service plant extract feed additive and preparation technology | |
KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
KR20170024689A (en) | Food composition for bowel movement promotion and diet using herbal material | |
CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
CN108902731A (en) | A kind of strengthening spleen and nourishing stomach promotes children's intelligence development and the noodles of body growth and preparation method thereof | |
CN108783443A (en) | A kind of tablet and preparation method thereof for internal organs conditioning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210827 |